Here's the line-up of experts for Tech Founders for Garvan, it's second to none. We hope that you can join us.
Prof Chris Goodnow
Chris Goodnow is the Executive Director of Garvan Institute of Medical Research. Chris is an internationally renowned immunologist. He joined Garvan in 2015 and is best known for integrating molecular genetics and genomics with immunology, for which he received numerous awards and election to the Australian Academy of Science, the UK Royal Society, and the US National Academy of Science.
Chris has had an extensive international research career. He has been a faculty member at Stanford University and the Australian National University and has been closely involved in several biotechnology start-up companies.
Mr Scott Farquhar
Scott Farquhar is the co-founder and co-CEO of Atlassian. Scott was awarded the ‘Australian IT Professional of the Year’ in 2004, and in 2006 was the youngest person ever to be awarded the ‘Australian Entrepreneur of the Year’ by Ernst & Young alongside co-founder and co-CEO Mike Cannon-Brookes.
Outside of Atlassian, Scott co-founded a private investment fund, Skip Capital, which focuses on fast-growing technology companies, and he lectures on entrepreneurship at his alma mater, the University of New South Wales.
Mr Nick Abrahams
Nick Abrahams is the Global Head of Technology and Innovation at Norton Rose Fulbright and has deep commercial expertise and global networks in the technology space. He is the Founder of leading online legal site, LawPath. He is a non-executive director on ASX300 software company, Integrated Research.
He is a director of the Sydney Film Festival and is on the board of the Vodafone Foundation, and past President of the Australian Communications and Media Law Association and writes regularly on technology and future trends for The Australian Financial Review. He is the author of two Kindle Business books: Digital Disruption in Australia and Big Data, Big Responsibilities: A Guide to Privacy & Data Security for Australian Business.
A/Prof Daniel MacArthur
Newly recruited to the Garvan Institute, Daniel MacArthur was an Institute member of is an institute member at the Broad Institute of MIT and Harvard, and co-director of the Broad’s Program in Medical and Population Genetics. Daniel's work revolves around the use of large-scale genomic data to interpret genetic variants, particularly in the context of rare, severe genetic diseases.
Daniel and his team have assembled the largest collection of sequences of the protein-coding region (exome) of the human genome, creating a resource called the Genome Aggregation Database (gnomAD). This collection currently contains DNA sequencing data from over 140,000 individuals, and is made publicly available for anyone to use. As a result it has become the default reference database for clinical genetics labs, and is accessed over 15,000 times every day. It also serves as the basis for the Human Knockout Project, an ambitious global endeavour seeking to characterize the clinical impact of the disruption of each of the 20,000 genes in the human genome.
A/Prof Joseph Powell
Joseph Powell is the head of the Garvan Weizmann Centre for Cellular Genomics, a Lab head at the Garvan Institute of Medical Research, and a Principal Research Fellow in the Faculty of Medicine, University of New South Wales.
After finishing his Ph.D. Joseph moved to Professor Peter Visscher’s (FRS, FAA) group at QIMR, and then the University of Queensland, where he helped form and lead an international consortium to study the genetic control of gene expression (the Consortium for the Architecture of Gene Expression). In 2015, whilst working at the Institute for Molecular Bioscience, Joseph and his team pioneered the use of single cell sequencing methods to understand the genetic control of disease, and cell development.
A/Prof Sarah Kummerfeld
Sarah Kummerfeld is the Scientific Head of the Kinghorn Centre for Clinical Genomics. She uses genomics to understand human disease and translate findings into clinical diagnostics and treatments. Sarah completed her PhD in Computational Biology at the University of Cambridge, working on protein structure and function prediction.
Her postdoctoral research at Stanford University studied the molecular basis of human ageing. Sarah has worked both in academia and industry, including 10 years as a Scientist at Genentech, based in the San Francisco Bay Area. At Genentech, she used large-scale genomics approaches to understand why only some patients respond to treatment and to identify diagnostic biomarkers that predict response to particular drugs. Sarah is dedicated to bringing applying advances in genomics research to benefit patients.
Mr David Barda
David Barda is an entrepreneur, executive and advisor specialising in technology commercialisation and early-stage ventures for biomedical technologies. David heads up business development and innovation at the Garvan Institute of Medical Research, that leads the world with its work in the areas of genomics, bioinformatics, cancer, and immunology.
David previously led a team commercialising medical technologies in Singapore with A*STAR, the national science, and technology agency. Prior to this, David has many years of experience founding and consulting to new ventures in the life sciences area with companies such as Anatomics, Saluda Medical and Simavita. David has an Honours degree in Computer Science from UNSW and has a Masters of Intellectual Property Law from Monash University and is an inventor on 24 granted patents. His interest areas include business models for precision medicine, AI for healthcare, genomics, bioinformatics, medical IOT, brain-computer interface, bioelectronic medicine, medical imaging and wearable sensors.